Impact of optimized Obstructive Sleep Apnea Therapy in Patients with Acute Coronary Syndrome: A Pilot Randomised Control Trial

niversity of Sydney0 个研究点目标入组 60 人开始时间: 2020年1月22日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•1. Patients with a recent (within 12 months of diagnosis) presentation of acute coronary syndrome (unstable angina, ST elevated myocardial infarction (EMI), non-STEMI).
•2. Patients diagnosed with moderate to severe obstructive sleep apnoea with significant hypoxia defined as an Oxygen Saturation Index 3% (ODI 3%) > 10 events/hour on polysomnogram.
•3. Clinically suitable for PAP and/or OAT treatment.
•4. Willingness to undergo either PAP, OAT or usual care for 6 months.

•1. Previous treatment for obstructive sleep apnea.
•2. Contraindications to CPAP (severe nasal obstruction) or oral appliance therapy (insufficient teeth or dental health issues).
•3. Women who are lactating or pregnant
•4. Driving risk, report an accident (or near miss accident) because of sleepiness in the last 6 months
•5. Need for immediate therapy as assessed by treating sleep physician.
•6. Patients with a history of psychological illness or conditions such as to interfere with the patients ability to understand the requirements of the study
•7. Coexisting sleep disorder, shift work, regular use of sedatives or narcotics, pre-existing lung disease (moderate to severe chronic obstructive pulmonary disease) or psychiatric disease; chronic kidney disease (eGFR<60).
•8. Central sleep apnea (defined as >20% of respiratory events being central events, rather than obstructive events)

发起方